TRCT
DYN icon

Tower Research Capital (TRC)’s Dyne Therapeutics DYN Stock Holding History

Tower Research Capital (TRC)’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$115K Sell
5,187
-6,441
-55% -$120K ﹤0.01% 2082
2026
Q1 		$211K Buy
11,628
+10,898
+1,493% +$188K 0.01% 1577
2025
Q4 		$14.3K Sell
730
-7,381
-91% -$140K ﹤0.01% 3358
2025
Q3 		$103K Sell
8,111
-2,384
-23% -$27.2K ﹤0.01% 1970
2025
Q2 		$99.9K Buy
10,495
+7,697
+275% +$84.7K ﹤0.01% 2377
2025
Q1 		$29.3K Sell
2,798
-13,220
-83% -$189K ﹤0.01% 2635
2024
Q4 		$377K Buy
16,018
+14,396
+888% +$426K 0.01% 1258
2024
Q3 		$58.3K Sell
1,622
-12,432
-88% -$495K ﹤0.01% 2639
2024
Q2 		$496K Buy
14,054
+13,477
+2,336% +$392K 0.01% 1351
2024
Q1 		$16.4K Sell
577
-6,218
-92% -$141K ﹤0.01% 3187
2023
Q4 		$90.4K Sell
6,795
-1,194
-15% -$11.7K ﹤0.01% 2725
2023
Q3 		$71.6K Sell
7,989
-414
-5% -$4.46K ﹤0.01% 2247
2023
Q2 		$94.5K Buy
8,403
+7,130
+560% +$84.1K ﹤0.01% 2061
2023
Q1 		$15K Buy
1,273
+538
+73% +$6.99K ﹤0.01% 3779
2022
Q4 		$9K Sell
735
-8,847
-92% -$102K ﹤0.01% 4189
2022
Q3 		$122K Buy
9,582
+7,757
+425% +$88.9K ﹤0.01% 2389
2022
Q2 		$13K Sell
1,825
-24,819
-93% -$171K ﹤0.01% 4202
2022
Q1 		$257K Buy
26,644
+25,596
+2,442% +$218K ﹤0.01% 1561
2021
Q4 		$12K Sell
1,048
-410
-28% -$5.76K ﹤0.01% 4266
2021
Q3 		$23K Sell
1,458
-307
-17% -$5.44K ﹤0.01% 3590
2021
Q2 		$37K Buy
1,765
+963
+120% +$18.1K ﹤0.01% 3277
2021
Q1 		$12K Buy
802
+353
+79% +$6.83K ﹤0.01% 4252
2020
Q4 		$9K Buy
449
+326
+265% +$6.45K ﹤0.01% 4376
2020
Q3 		$2K Buy
+123
New +$2.7K ﹤0.01% 4578

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Tower Research Capital (TRC)'s DYN Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Dyne Therapeutics (DYN) stake by 55% in Q2 2026, selling an estimated $120K and leaving 5,187 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #2082.

Tower Research Capital (TRC) first reported a position in DYN in Q3 2020 and has held it in 24 quarters since. The position peaked at $496K in Q2 2024. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Tower Research Capital (TRC) held 5,187 shares of Dyne Therapeutics worth $115K as of Q2 2026.
  • Tower Research Capital (TRC) sold 6,441 Dyne Therapeutics shares in Q2 2026, an estimated $120K.
  • Dyne Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2082 holding.
  • Tower Research Capital (TRC) first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Tower Research Capital (TRC)'s Dyne Therapeutics position peaked at $496K in Q2 2024.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.